Anticancer resistance remains a major obstacle in achieving successful outcomes in cancer treatment. Understanding the pharmacological mechanisms underlying resistance is crucial for developing effective strategies to overcome it. This article provides a comprehensive overview of the various pharmacological mechanisms contributing to anticancer resistance, including drug efflux pumps, altered drug targets, drug metabolism and inactivation, DNA repair and damage response, activation of alternative signaling pathways, the tumor microenvironment, epithelial-mesenchymal transition, and cancer stem cells. The article discusses the future directions in this field, such as combination therapies, personalized medicine, immunotherapy, novel drug delivery systems, and biomarker development. Combining multiple strategies and adopting a personalized approach is essential to overcome anticancer resistance and improve treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Khatri et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: